 <h1>Subvenite Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>lamotrigine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about lamotrigine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Subvenite.</p><h2>In Summary</h2><p><b>Common side effects of Subvenite include:</b> ataxia, skin rash, headache, insomnia, and nausea. <b>Other side effects include:</b> infection, dyspepsia, abnormal gait, constipation, and drowsiness.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to lamotrigine: oral tablet, oral tablet chewable, oral tablet disintegrating, oral tablet extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet; Tablet, Chewable; Tablet, Disintegrating; Tablet, Extended Release)</p><p>Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include: (1) coadministration with valproate; (2) exceeding recommended initial dose of lamotrigine; or (3) exceeding recommended dose escalation for lamotrigine. Benign rashes are also caused by lamotrigine; however, it is not possible to predict which rashes will prove to be serious or life threatening. Lamotrigine should be discontinued at the first sign of rash, unless the rash is clearly not drug related.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, lamotrigine (the active ingredient contained in Subvenite) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking lamotrigine:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>changes in vision</li>
<li>chest pain, discomfort, or tightness</li>
<li>clumsiness or unsteadiness</li>
<li>decreased urine output</li>
<li>dilated neck veins</li>
<li>double vision</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>nausea</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>poor coordination</li>
<li>seizure that will not stop</li>
<li>skin rash</li>
<li>sweating</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>chest pain</li>
<li>confusion</li>
<li>continuous, uncontrolled back and forth or rolling eye movements</li>
<li>depression</li>
<li>increase in seizures</li>
<li>infection</li>
<li>irritability</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chills</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>itching</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>memory loss</li>
<li>muscle cramps, pain, or weakness</li>
<li>red or irritated eyes</li>
<li>runny nose</li>
<li>shivering</li>
<li>small red or purple spots on the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swelling of the face, mouth, hands, or feet</li>
<li>swollen lymph nodes</li>
<li>trouble sleeping</li>
<li>unusual bleeding or bruising</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>bloating</li>
<li>blood in the urine</li>
<li>bloody, black or tarry stools</li>
<li>bluish lips or skin</li>
<li>constipation</li>
<li>cough</li>
<li>coughing or vomiting blood</li>
<li>difficulty with swallowing</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>general body swelling</li>
<li>heartburn</li>
<li>high fever</li>
<li>hoarseness</li>
<li>lightheadedness</li>
<li>loss of balance control</li>
<li>lower back or side pain</li>
<li>mask-like face</li>
<li>muscle spasms</li>
<li>nosebleeds</li>
<li>not breathing</li>
<li>pain or burning in the throat</li>
<li>painful or difficult urination</li>
<li>pains in the stomach or side, possibly radiating to the back</li>
<li>pale skin</li>
<li>persistent bleeding or oozing from puncture sites, mouth, or nose</li>
<li>rapid, shallow breathing</li>
<li>redness, soreness, or itching skin</li>
<li>shuffling walk</li>
<li>slowed movement</li>
<li>slurred speech</li>
<li>sores, welting, or blisters</li>
<li>stiffness of the arms and legs</li>
<li>swollen or painful glands</li>
<li>tic-like (jerky) movements</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking lamotrigine:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Clumsiness or unsteadiness (severe)</li>
<li>continuous, uncontrolled back and forth or rolling eye movements (severe)</li>
<li>dizziness (severe)</li>
<li>drowsiness (severe)</li>
<li>dryness of the mouth (severe)</li>
<li>headache (severe)</li>
<li>increased heart rate</li>
<li>loss of consciousness</li>
<li>slurred speech (severe)</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of lamotrigine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Dizziness</li>
<li>drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Indigestion</li>
<li>loss of strength</li>
<li>menstrual pain</li>
<li>pain</li>
<li>trembling or shaking</li>
<li>trouble with sleeping</li>
<li>unusual weight loss</li>
</ul><p>
<!-- end oral tablet, oral tablet chewable, oral tablet disintegrating, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lamotrigine: oral tablet, oral tablet disintegrating, oral tablet dispersible, oral tablet extended release</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, and rash.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>In cases of hemophagocytic lymphohistiocytosis (HLH), patients have presented with signs of systemic inflammation (fever, rash, hepatosplenomegaly, and organ system dysfunction) and blood dyscrasias.  Symptoms have been reported within 8 to 24 days.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Progressive immunosuppression, Lupus-like reaction, vasculitis, drug reaction with eosinophilia and systemic symptoms (DRESS), hemophagocytic lymphohistiocytosis (HLH)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reaction, chills, malaise<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (38%), headache (29%), ataxia (22%), somnolence (14%)</p>
<p><b>Common</b> (1% to 10%): Seizure exacerbation, incoordination, insomnia, tremor, speech disorder, amnesia, hypoesthesia, pain, gait abnormality, vertigo, dyspraxia, confusion, paresthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Akathisia, aphasia, central nervous system depression, dysarthria, dyskinesia, hyperkinesia, hypertonia, movement disorder, myoclonus, sudden unexplained death in Epilepsy (SUDEP)</p>
<p><b>Rare</b> (less than 0.1%): Choreoathetosis, dystonia, extrapyramidal syndrome, faintness, grand mal seizures, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, neuralgia, muscle spasm, neuralgia, paralysis, peripheral neuritis</p>
<p><b>Very rare</b> (less than 0.01%): Muscle spasm, paralysis, peripheral neuritis</p>
<p><b>Postmarketing reports</b>: Exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson's disease, tics<sup>[Ref]</sup></p><p>Sudden unexplained death in epilepsy (SUDEP) was reported in 20 of 4700 patients with epilepsy during premarketing development.  While this exceeds the expected rate in healthy populations, it is within the range for patients with epilepsy.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, irritability, disturbance of concentration, emotional lability, abnormal thinking, nervousness</p>
<p><b>Uncommon</b> (0.1% to 1%): Apathy, euphoria, hallucinations, hostility, depersonalization, memory decrease, mind racing, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, stupor, suicidal ideation</p>
<p><b>Rare</b> (less than 0.1%): Delirium, delusions, dysphoria, manic depression reaction, neurosis</p>
<p><b>Postmarketing reports</b>: Aggression, nightmares<sup>[Ref]</sup></p><p>Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior.  Pooled analyses of 199 placebo-controlled clinical trials of 11 different AEDs (monotherapy or adjunctive therapy) showed twice the risk compared with placebo patients; an estimated incidence of 0.43% (n=27,863) in AED-treated patients compared to 0.24% (n=16,029) in placebo.  The median treatment duration was 12 weeks.  There were 4 suicides in AED-treated patients (placebo=0).  The risk of suicidal thoughts or behavior was considered similar among the drugs studied despite their varying mechanisms of action suggesting the risk applies to all AEDs used for any indication.  Additionally, the risk did not vary substantially by age.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Diplopia (28%), blurred vision (16%)</p>
<p><b>Common</b> (1% to 10%): Vision abnormality, nystagmus, photosensitivity, amblyopia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormality of accommodation, conjunctivitis, dry eyes, photophobia</p>
<p><b>Rare</b> (less than 0.1%): Lacrimation disorder, oscillopsia, ptosis, strabismus, uveitis, visual field defect<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (20%), nausea (19%), diarrhea (10%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, dyspepsia, constipation, anorexia, dry mouth, rectal hemorrhage, peptic ulcer, flatulence</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysphagia, eructation, gastritis, gingivitis, increased appetite, increased salivation, mouth ulceration</p>
<p><b>Rare</b> (less than 0.1%): Gastrointestinal hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, melena, stomach ulcer, stomatitis, tongue edema</p>
<p><b>Very rare</b> (less than 0.01%): Pancreatitis, esophagitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Rhinitis (14%)</p>
<p><b>Common</b> (1% to 10%): Pharyngitis, increased cough, epistaxis, dyspnea, bronchitis, sinusitis, bronchospasm</p>
<p><b>Uncommon</b> (0.1% to 1%): Yawn</p>
<p><b>Rare</b> (less than 0.1%): Hiccup, hyperventilation</p>
<p><b>Postmarketing reports</b>: Apnea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In adult patients (n=3348), serious rash associated with hospitalization and discontinuation was reported in 0.3% of patients in premarketing epilepsy trials.  In bipolar trials, serious rash occurred in 0.08% of patients receiving this drug as initial monotherapy and 0.13% of patients receiving this drug as adjunctive therapy.  In worldwide postmarketing experience, rash-related death has been reported, but the numbers are too few to permit a precise estimate of rate.  </p>
<p></p>
<p>In a prospectively followed cohort of pediatric patients 2 to 17 years old, the incidence of serious rash was approximately 0.3% to 0.8%.  In a prospectively followed cohort of patients 2 to 16 years old (n=1983), 1 rash-related death occurred in a patient with epilepsy taking this drug as adjunctive therapy.  </p>
<p></p>
<p>Evidence has show the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in both adult and pediatric patients.  In pediatric patients who used valproate concomitantly for epilepsy, 1.2% (6 of 482) experienced a serious rash (placebo=0.6%).  In adults, 1% of patients of patients receiving this drug in combination with valproate (n=584) experienced a rash (placebo=0.16%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rash (14%)</p>
<p><b>Common</b> (1% to 10%): Contact dermatitis, dry skin, sweating, eczema, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, urticaria, ecchymosis, leukopenia</p>
<p><b>Rare</b> (less than 0.1%): Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson syndrome, vesiculobullous rash, anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytosis, macrocytic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea, vaginitis, amenorrhea, libido increase, urinary tract infection (both male and female), urinary frequency</p>
<p><b>Uncommon</b> (0.1% to 1%): Libido decreased, abnormal ejaculation, hematuria, impotence, menorrhagia, polyuria, urinary incontinence</p>
<p><b>Rare</b> (less than 0.1%): Anorgasmia, breast abscess, breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation, nocturia, urinary retention, urinary urgency<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (15%), accidental injury (14%)</p>
<p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Uncommon</b> (0.1% to 1%): Ear pain, taste perversion, tinnitus</p>
<p><b>Rare</b> (less than 0.1%): Alcohol intolerance, deafness, taste loss, parosmia, taste loss<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight decrease, weight gain, peripheral edema, facial edema</p>
<p><b>Rare</b> (less than 0.1%): Bilirubinemia, general edema, gamma glutamyl transpeptidase increase, hyperglycemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Neck pain, arthralgia, myalgia, decreased reflexes, back pain, increased reflexes, asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthritis, leg cramps, myasthenia, twitching</p>
<p><b>Rare</b> (less than 0.1%): Bursitis, muscle atrophy, pathological fracture, tendinous contracture</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis (among patients experiencing hypersensitivity reactions)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, migraine</p>
<p><b>Uncommon</b> (0.1% to 1%): Flushing, hot flashes, hypertension, palpitations, postural hypotension, syncope, tachycardia, vasodilation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Agranulocytosis, hemolytic anemia, lymphadenopathy not associated with hypersensitivity disorder<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Liver function tests abnormal, aspartate transaminase (AST) increased</p>
<p><b>Rare</b> (less than 0.1%): Hepatitis, alanine transaminase ALT) increased, acute kidney failure, kidney failure, kidney pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. LaMICtal XR (lamoTRIgine)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_2">2. "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_5">5. Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997): 720-3</p><p id="ref_6">6. Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996): 1041</p><p id="ref_7">7. Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998): 392-8</p><p id="ref_8">8. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996): 1597</p><p id="ref_9">9. Hilas O,  Charneski L "Lamotrigine-induced Stevens-Johnson syndrome." Am J Health Syst Pharm 64 (2007): 273-275</p><p id="ref_10">10. Boot B "Recurrent lamotrigine-induced aseptic meningitis." Epilepsia 50 (2009): 968-9</p><p id="ref_11">11. Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989): 312-21</p><p id="ref_12">12. Desarkar P,  Sinha VK "Lamotrigine-induced severe manic switch." Aust N Z J Psychiatry 40 (2006): 718</p><p id="ref_13">13. Margolese HC,  Beauclair L,  Szkrumelak N,  Chouinard G "Hypomania Induced by Adjunctive Lamotrigine." Am J Psychiatry 160 (2003): 183-184</p><p id="ref_14">14. Uher R,  Jones HM "Hallucinations during lamotrigine treatment of bipolar disorder." Am J Psychiatry 163 (2006): 749-50</p><p id="ref_15">15. Mueller TH,  Beeber AR "Delirium From Valproic Acid With Lamotrigine." Am J Psychiatry 161 (2004): 1128-1129</p><p id="ref_16">16. Verma A, Miller P, Carwile ST, Husain AM, Radtke "Lamotrigine-induced blepharospam." Pharmacotherapy 19 (1999): 877-80</p><p id="ref_17">17. Saravanan N,  Musibay Otaiku O,  Namushi Namushi R "Interstitial pneumonitis during lamotrigine therapy." Br J Clin Pharmacol 60 (2005): 666-7</p><p id="ref_18">18. Hillemacher T,  Bleich S,  Kornhuber J,  Frieling H "Hair loss as a side effect of lamotrigine treatment." Am J Psychiatry 163 (2006): 1451</p><p id="ref_19">19. Schwartz R,  Avello E,  Palisson F "Lamotrigine-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and amniotic membranes." Arch Dermatol 144 (2008): 724-6</p><p id="ref_20">20. Bowden CL,  Calabrese JR,  Ketter TA,  Sachs GS,  White RL,  Thompson TR "Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder." Am J Psychiatry 163 (2006): 1199-201</p><p id="ref_21">21. Avoni P,  Contin M,  Riva R,  Albani F,  Liguori R,  Baruzzi A "Dysgeusia in epileptic patients treated with lamotrigine: Report of three cases." Neurology 57 (2001): 1521</p><p id="ref_22">22. FDA. U.S Food &amp; Drug Administration "FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal) Available from: URL: https://www.fda.gov/Drugs/DrugSafety/ucm605470.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Comm"   ([2018, Apr 25]):</p><p id="ref_23">23. Esfahani FE, Dasheiff RM "Anemia associated with lamotrigine." Neurology 49 (1997): 306-7</p><p id="ref_24">24. Fadul CE,  Meyer LP,  Jobst BC,  Cornell CJ,  Lewis LD "Agranulocytosis Associated with Lamotrigine in a Patient with Low-grade Glioma." Epilepsia 43 (2002): 199-200</p><p id="ref_25">25. Ouellet G,  Tremblay L,  Marleau D "Fulminant hepatitis induced by lamotrigine." South Med J 102 (2009): 82-4</p><p id="ref_26">26. Moeller KE,  Wei L,  Jewell AD,  Carver LA "Acute hepatotoxicity associated with lamotrigine." Am J Psychiatry 165 (2008): 539-40</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>If you are taking lamotrigine how long does it take to get out of your system?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Subvenite (lamotrigine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>FDA Alerts (5)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Lamictal, Lamictal XR, Lamictal ODT, Lamictal CD</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lamotrigine: oral tablet, oral tablet disintegrating, oral tablet dispersible, oral tablet extended release</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, and rash.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>In cases of hemophagocytic lymphohistiocytosis (HLH), patients have presented with signs of systemic inflammation (fever, rash, hepatosplenomegaly, and organ system dysfunction) and blood dyscrasias.  Symptoms have been reported within 8 to 24 days.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Progressive immunosuppression, Lupus-like reaction, vasculitis, drug reaction with eosinophilia and systemic symptoms (DRESS), hemophagocytic lymphohistiocytosis (HLH)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reaction, chills, malaise<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (38%), headache (29%), ataxia (22%), somnolence (14%)</p><p><b>Common</b> (1% to 10%): Seizure exacerbation, incoordination, insomnia, tremor, speech disorder, amnesia, hypoesthesia, pain, gait abnormality, vertigo, dyspraxia, confusion, paresthesia</p><p><b>Uncommon</b> (0.1% to 1%): Akathisia, aphasia, central nervous system depression, dysarthria, dyskinesia, hyperkinesia, hypertonia, movement disorder, myoclonus, sudden unexplained death in Epilepsy (SUDEP)</p><p><b>Rare</b> (less than 0.1%): Choreoathetosis, dystonia, extrapyramidal syndrome, faintness, grand mal seizures, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, neuralgia, muscle spasm, neuralgia, paralysis, peripheral neuritis</p><p><b>Very rare</b> (less than 0.01%): Muscle spasm, paralysis, peripheral neuritis</p><p><b>Postmarketing reports</b>: Exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson's disease, tics<sup>[Ref]</sup></p><p>Sudden unexplained death in epilepsy (SUDEP) was reported in 20 of 4700 patients with epilepsy during premarketing development.  While this exceeds the expected rate in healthy populations, it is within the range for patients with epilepsy.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, irritability, disturbance of concentration, emotional lability, abnormal thinking, nervousness</p><p><b>Uncommon</b> (0.1% to 1%): Apathy, euphoria, hallucinations, hostility, depersonalization, memory decrease, mind racing, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, stupor, suicidal ideation</p><p><b>Rare</b> (less than 0.1%): Delirium, delusions, dysphoria, manic depression reaction, neurosis</p><p><b>Postmarketing reports</b>: Aggression, nightmares<sup>[Ref]</sup></p><p>Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior.  Pooled analyses of 199 placebo-controlled clinical trials of 11 different AEDs (monotherapy or adjunctive therapy) showed twice the risk compared with placebo patients; an estimated incidence of 0.43% (n=27,863) in AED-treated patients compared to 0.24% (n=16,029) in placebo.  The median treatment duration was 12 weeks.  There were 4 suicides in AED-treated patients (placebo=0).  The risk of suicidal thoughts or behavior was considered similar among the drugs studied despite their varying mechanisms of action suggesting the risk applies to all AEDs used for any indication.  Additionally, the risk did not vary substantially by age.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Diplopia (28%), blurred vision (16%)</p><p><b>Common</b> (1% to 10%): Vision abnormality, nystagmus, photosensitivity, amblyopia</p><p><b>Uncommon</b> (0.1% to 1%): Abnormality of accommodation, conjunctivitis, dry eyes, photophobia</p><p><b>Rare</b> (less than 0.1%): Lacrimation disorder, oscillopsia, ptosis, strabismus, uveitis, visual field defect<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (20%), nausea (19%), diarrhea (10%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, dyspepsia, constipation, anorexia, dry mouth, rectal hemorrhage, peptic ulcer, flatulence</p><p><b>Uncommon</b> (0.1% to 1%): Dysphagia, eructation, gastritis, gingivitis, increased appetite, increased salivation, mouth ulceration</p><p><b>Rare</b> (less than 0.1%): Gastrointestinal hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, melena, stomach ulcer, stomatitis, tongue edema</p><p><b>Very rare</b> (less than 0.01%): Pancreatitis, esophagitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Rhinitis (14%)</p><p><b>Common</b> (1% to 10%): Pharyngitis, increased cough, epistaxis, dyspnea, bronchitis, sinusitis, bronchospasm</p><p><b>Uncommon</b> (0.1% to 1%): Yawn</p><p><b>Rare</b> (less than 0.1%): Hiccup, hyperventilation</p><p><b>Postmarketing reports</b>: Apnea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In adult patients (n=3348), serious rash associated with hospitalization and discontinuation was reported in 0.3% of patients in premarketing epilepsy trials.  In bipolar trials, serious rash occurred in 0.08% of patients receiving this drug as initial monotherapy and 0.13% of patients receiving this drug as adjunctive therapy.  In worldwide postmarketing experience, rash-related death has been reported, but the numbers are too few to permit a precise estimate of rate.  </p><p></p><p>In a prospectively followed cohort of pediatric patients 2 to 17 years old, the incidence of serious rash was approximately 0.3% to 0.8%.  In a prospectively followed cohort of patients 2 to 16 years old (n=1983), 1 rash-related death occurred in a patient with epilepsy taking this drug as adjunctive therapy.  </p><p></p><p>Evidence has show the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in both adult and pediatric patients.  In pediatric patients who used valproate concomitantly for epilepsy, 1.2% (6 of 482) experienced a serious rash (placebo=0.6%).  In adults, 1% of patients of patients receiving this drug in combination with valproate (n=584) experienced a rash (placebo=0.16%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rash (14%)</p><p><b>Common</b> (1% to 10%): Contact dermatitis, dry skin, sweating, eczema, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, urticaria, ecchymosis, leukopenia</p><p><b>Rare</b> (less than 0.1%): Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson syndrome, vesiculobullous rash, anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytosis, macrocytic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea, vaginitis, amenorrhea, libido increase, urinary tract infection (both male and female), urinary frequency</p><p><b>Uncommon</b> (0.1% to 1%): Libido decreased, abnormal ejaculation, hematuria, impotence, menorrhagia, polyuria, urinary incontinence</p><p><b>Rare</b> (less than 0.1%): Anorgasmia, breast abscess, breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation, nocturia, urinary retention, urinary urgency<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (15%), accidental injury (14%)</p><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Uncommon</b> (0.1% to 1%): Ear pain, taste perversion, tinnitus</p><p><b>Rare</b> (less than 0.1%): Alcohol intolerance, deafness, taste loss, parosmia, taste loss<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight decrease, weight gain, peripheral edema, facial edema</p><p><b>Rare</b> (less than 0.1%): Bilirubinemia, general edema, gamma glutamyl transpeptidase increase, hyperglycemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Neck pain, arthralgia, myalgia, decreased reflexes, back pain, increased reflexes, asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Arthritis, leg cramps, myasthenia, twitching</p><p><b>Rare</b> (less than 0.1%): Bursitis, muscle atrophy, pathological fracture, tendinous contracture</p><p><b>Postmarketing reports</b>: Rhabdomyolysis (among patients experiencing hypersensitivity reactions)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, migraine</p><p><b>Uncommon</b> (0.1% to 1%): Flushing, hot flashes, hypertension, palpitations, postural hypotension, syncope, tachycardia, vasodilation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Agranulocytosis, hemolytic anemia, lymphadenopathy not associated with hypersensitivity disorder<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy</p><p><b>Uncommon</b> (0.1% to 1%): Liver function tests abnormal, aspartate transaminase (AST) increased</p><p><b>Rare</b> (less than 0.1%): Hepatitis, alanine transaminase ALT) increased, acute kidney failure, kidney failure, kidney pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. LaMICtal XR (lamoTRIgine)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_2">2. "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_5">5. Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997): 720-3</p><p id="ref_6">6. Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996): 1041</p><p id="ref_7">7. Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998): 392-8</p><p id="ref_8">8. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996): 1597</p><p id="ref_9">9. Hilas O,  Charneski L "Lamotrigine-induced Stevens-Johnson syndrome." Am J Health Syst Pharm 64 (2007): 273-275</p><p id="ref_10">10. Boot B "Recurrent lamotrigine-induced aseptic meningitis." Epilepsia 50 (2009): 968-9</p><p id="ref_11">11. Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989): 312-21</p><p id="ref_12">12. Desarkar P,  Sinha VK "Lamotrigine-induced severe manic switch." Aust N Z J Psychiatry 40 (2006): 718</p><p id="ref_13">13. Margolese HC,  Beauclair L,  Szkrumelak N,  Chouinard G "Hypomania Induced by Adjunctive Lamotrigine." Am J Psychiatry 160 (2003): 183-184</p><p id="ref_14">14. Uher R,  Jones HM "Hallucinations during lamotrigine treatment of bipolar disorder." Am J Psychiatry 163 (2006): 749-50</p><p id="ref_15">15. Mueller TH,  Beeber AR "Delirium From Valproic Acid With Lamotrigine." Am J Psychiatry 161 (2004): 1128-1129</p><p id="ref_16">16. Verma A, Miller P, Carwile ST, Husain AM, Radtke "Lamotrigine-induced blepharospam." Pharmacotherapy 19 (1999): 877-80</p><p id="ref_17">17. Saravanan N,  Musibay Otaiku O,  Namushi Namushi R "Interstitial pneumonitis during lamotrigine therapy." Br J Clin Pharmacol 60 (2005): 666-7</p><p id="ref_18">18. Hillemacher T,  Bleich S,  Kornhuber J,  Frieling H "Hair loss as a side effect of lamotrigine treatment." Am J Psychiatry 163 (2006): 1451</p><p id="ref_19">19. Schwartz R,  Avello E,  Palisson F "Lamotrigine-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and amniotic membranes." Arch Dermatol 144 (2008): 724-6</p><p id="ref_20">20. Bowden CL,  Calabrese JR,  Ketter TA,  Sachs GS,  White RL,  Thompson TR "Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder." Am J Psychiatry 163 (2006): 1199-201</p><p id="ref_21">21. Avoni P,  Contin M,  Riva R,  Albani F,  Liguori R,  Baruzzi A "Dysgeusia in epileptic patients treated with lamotrigine: Report of three cases." Neurology 57 (2001): 1521</p><p id="ref_22">22. FDA. U.S Food &amp; Drug Administration "FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal) Available from: URL: https://www.fda.gov/Drugs/DrugSafety/ucm605470.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Comm"   ([2018, Apr 25]):</p><p id="ref_23">23. Esfahani FE, Dasheiff RM "Anemia associated with lamotrigine." Neurology 49 (1997): 306-7</p><p id="ref_24">24. Fadul CE,  Meyer LP,  Jobst BC,  Cornell CJ,  Lewis LD "Agranulocytosis Associated with Lamotrigine in a Patient with Low-grade Glioma." Epilepsia 43 (2002): 199-200</p><p id="ref_25">25. Ouellet G,  Tremblay L,  Marleau D "Fulminant hepatitis induced by lamotrigine." South Med J 102 (2009): 82-4</p><p id="ref_26">26. Moeller KE,  Wei L,  Jewell AD,  Carver LA "Acute hepatotoxicity associated with lamotrigine." Am J Psychiatry 165 (2008): 539-40</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>If you are taking lamotrigine how long does it take to get out of your system?</li>
</ul><h2>More about Subvenite (lamotrigine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>FDA Alerts (5)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>